Rock Springs Capital BMEA Position
Exited6-Fund ConvergenceRock Springs Capital exited their position in Biomea Fusion Inc. (BMEA) in Q1 2025, after holding the stock for 9 quarters.
The position was first reported in Q1 2023 and has been tracked across 9 quarterly 13F filings.
BMEA is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for icovamenib 100mg in 440 days (Jun 30, 2027), making the timing of Rock Springs's position particularly relevant.
Short interest stands at 20.0% of float with 14.1 days to cover, indicating significant bearish positioning against the stock.
About Biomea Fusion Inc.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Full company profile →Short Interest
20.0%
14.1 days to cover
Rock Springs Capital BMEA Position History
Frequently Asked Questions
Does Rock Springs Capital own BMEA?
No. Rock Springs Capital exited their position in Biomea Fusion Inc. (BMEA) in Q1 2025. They previously held the stock for 9 quarters.
How many hedge funds own BMEA?
6 specialist biotech hedge funds currently hold BMEA, including Cormorant Asset Management, Baker Bros. Advisors, Driehaus Capital and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy BMEA?
Rock Springs Capital's position in BMEA was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's BMEA position increasing or decreasing?
Rock Springs Capital completely exited their BMEA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BMEACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →